<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137693</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18596</org_study_id>
    <nct_id>NCT03137693</nct_id>
  </id_info>
  <brief_title>Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer</brief_title>
  <official_title>A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves a course of radiation to the tumor that is delivered BEFORE surgery. The&#xD;
      type of radiation is called stereotactic ablative body radiation therapy (SABR). The purpose&#xD;
      of this study is to evaluate the effects, good and/or bad, of pre-operative SABR specifically&#xD;
      focusing on its ability to reduce the chances that additional breast surgery will be needed,&#xD;
      reducing the amount of breast/heart/lung tissue that is irradiated, and to study the&#xD;
      tumor-tissue effects of SABR. The usual treatment for patients with early-stage breast cancer&#xD;
      who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery,&#xD;
      targeting either the whole breast or part of the breast.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no responders/lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Pathologic Complete Response (pCR)</measure>
    <time_frame>6 weeks post SABR</time_frame>
    <description>Rate of pathologic complete response following pre-operative SABR for early-stage breast carcinoma. pCR: The absence of residual invasive disease in the breast and in the axillary lymph nodes at the completion of the neoadjuvant treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Cancer Female</condition>
  <condition>Breast Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Change in Procedure Scheduling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care Schedule Variation: SABR</intervention_name>
    <description>SABR will be delivered over 3 days, prior to surgery.</description>
    <arm_group_label>Change in Procedure Scheduling</arm_group_label>
    <other_name>radiotherapy</other_name>
    <other_name>Stereotactic Ablative Body Radiation Therapy (SABR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast-conserving Surgery</intervention_name>
    <description>Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.</description>
    <arm_group_label>Change in Procedure Scheduling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent document prior to conducting any&#xD;
             study related assessments or procedures.&#xD;
&#xD;
          -  Histologically proven invasive adenocarcinoma of breast.&#xD;
&#xD;
          -  Must have marker clip indicating location of target tumor in breast.&#xD;
&#xD;
          -  Unifocal tumor less than or equal to 2 cm based on contrast-enhanced prone-breast MRI.&#xD;
&#xD;
          -  Must be clinically and radiographically node negative (N0) to participate on this&#xD;
             protocol. Clinically suspicious regional nodes by imaging or physical exam require&#xD;
             biopsy evaluation to exclude disease involvement.&#xD;
&#xD;
          -  Appropriate candidate for breast-conserving surgery based on multi-disciplinary&#xD;
             assessment.&#xD;
&#xD;
          -  Females age â‰¥ 50 years.&#xD;
&#xD;
          -  Able to tolerate prone body positioning during radiation therapy.&#xD;
&#xD;
          -  No prior ipsilateral-breast or thoracic radiotherapy.&#xD;
&#xD;
          -  As defined on MRI, target lesion must be at least 10 mm distance from skin (defined as&#xD;
             volume encompassing first 3 mm from breast surface).&#xD;
&#xD;
          -  Must be estrogen receptor (ER) positive.&#xD;
&#xD;
          -  Must be negative for Her-2 amplification. (Either 1+ on semi-quantitative evaluation&#xD;
             of immunostain or negative by fluorescent in-situ hybridization).&#xD;
&#xD;
          -  No implanted hardware or other material that would prohibit appropriate treatment&#xD;
             planning or treatment delivery in the investigator's opinion.&#xD;
&#xD;
          -  No history of an invasive malignancy (other than this breast cancer, or non-metastatic&#xD;
             basal or squamous skin cancers) in the last 5 years.&#xD;
&#xD;
          -  Must not have received nor be planned for neoadjuvant chemotherapy prior to SABR or&#xD;
             surgery.&#xD;
&#xD;
          -  ECOG performance status less than 2.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative urine pregnancy test prior to&#xD;
             simulation and within seven days of SABR start.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have invasive lobular carcinoma.&#xD;
&#xD;
          -  Have a Tumor &gt; 2 cm as measured on prone contrast-enhanced breast MRI.&#xD;
&#xD;
          -  Have presence of histologically proven lymph node disease.&#xD;
&#xD;
          -  Are not a candidate for breast conserving surgery.&#xD;
&#xD;
          -  Have had prior ipsilateral-breast or thoracic radiotherapy.&#xD;
&#xD;
          -  History of scleroderma or lupus erythematosus with either cutaneous manifestation or&#xD;
             requiring active treatment.&#xD;
&#xD;
          -  An MRI defined target tumor that is within 10 mm of skin (defined as volume&#xD;
             encompassing first 3 mm from skin surface).&#xD;
&#xD;
          -  Have amplification of Her-2 (Either 3+ by semi-quantitative immunostain or positive by&#xD;
             Fluorescent in-situ hybridization (FISH)).&#xD;
&#xD;
          -  Have implanted hardware or other material that would prohibit appropriate treatment&#xD;
             planning or treatment delivery in the investigator's opinion.&#xD;
&#xD;
          -  History of an invasive malignancy (other than this breast cancer, or non-metastatic&#xD;
             basal or squamous skin cancers) in the last 5 years.&#xD;
&#xD;
          -  Have received or plan to receive neoadjuvant chemotherapy either before radiotherapy&#xD;
             or before surgery.&#xD;
&#xD;
          -  A known carrier of BRCA1 or BRCA2 gene mutation.&#xD;
&#xD;
          -  Pregnant or unwilling to undergo pregnancy screening.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Montejo</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>November 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2020</results_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>histologically proven</keyword>
  <keyword>invasive adenocarcinoma of breast</keyword>
  <keyword>node negative (N0)</keyword>
  <keyword>breast-conserving surgery</keyword>
  <keyword>negative for Her-2 amplification</keyword>
  <keyword>estrogen receptor (ER) positive</keyword>
  <keyword>progesterone receptor (PR) positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03137693/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants who received Stereotactic Ablative Body Radiotherapy (SABR) prior to breast surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants who received Stereotactic Ablative Body Radiotherapy (SABR) prior to breast surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Pathologic Complete Response (pCR)</title>
        <description>Rate of pathologic complete response following pre-operative SABR for early-stage breast carcinoma. pCR: The absence of residual invasive disease in the breast and in the axillary lymph nodes at the completion of the neoadjuvant treatment.</description>
        <time_frame>6 weeks post SABR</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who received Stereotactic Ablative Body Radiotherapy (SABR) prior to breast surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Pathologic Complete Response (pCR)</title>
          <description>Rate of pathologic complete response following pre-operative SABR for early-stage breast carcinoma. pCR: The absence of residual invasive disease in the breast and in the axillary lymph nodes at the completion of the neoadjuvant treatment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 11 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants who received Stereotactic Ablative Body Radiotherapy (SABR) prior to breast surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dermatitis radiation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Montejo, MD</name_or_title>
      <organization>Moffitt Cancer Center</organization>
      <phone>813-745-8424</phone>
      <email>Michael.Montejo@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

